Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: J Immunol. 2011 Jun 22;187(3):1097–1105. doi: 10.4049/jimmunol.1003496

Figure 4. T cells from diabetic mice are more susceptible than T cells from prediabetic mice to the effects of 10F.2H11 antibody.

Figure 4

CD4+ and CD8+ T cells from prediabetic (A) or diabetic (B) NOD females were transferred i.v. into NOD SCID recipients which were then treated with 0.5 mg antibody i.p. on day 0, followed by 0.25 mg on days 2, 4, 6, 8 and 10. *p<0.05 over the first 59 days for 10F.9G2 vs. 10F.2H11 treatment. For transfers from diabetic donors, the effects of 10F.9G2 vs. 10F.2H11 mAb administration were not significantly different over any time frame. Data are pooled from two independent experiments with similar results; n = at least 9 per group. Pancreata for histology were harvested 10 days after transfer of prediabetic (C) or diabetic (D) T cells. Left panels – 10F.9G2 (insulitis in C and D); middle panels – 10F.2H11 (no insulitis in C, insulitis in D); right panels – Rat IgG2b isotype control (no insulitis in C or D).